Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares Outstanding
Ratios

Zhengye Biotechnology Holding (ZYBT) Accumulated Depreciation & Amortization (2023 - 2025)

Zhengye Biotechnology Holding has reported Accumulated Depreciation & Amortization over the past 3 years, most recently at $18.5 million for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 30.49% to $18.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.5 million through Dec 2025, up 30.49% year-over-year, with the annual reading at $18.3 million for FY2025, 30.87% up from the prior year.
  • Accumulated Depreciation & Amortization was $18.5 million for Q4 2025 at Zhengye Biotechnology Holding, up from $14.2 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $18.5 million in Q4 2025 and troughed at $11.8 million in Q4 2023.
  • The 3-year median for Accumulated Depreciation & Amortization is $14.2 million (2024), against an average of $14.8 million.
  • Year-over-year, Accumulated Depreciation & Amortization rose 20.07% in 2024 and then skyrocketed 30.49% in 2025.
  • A 3-year view of Accumulated Depreciation & Amortization shows it stood at $11.8 million in 2023, then rose by 20.07% to $14.2 million in 2024, then skyrocketed by 30.49% to $18.5 million in 2025.
  • Per Business Quant, the three most recent readings for ZYBT's Accumulated Depreciation & Amortization are $18.5 million (Q4 2025), $14.2 million (Q4 2024), and $11.8 million (Q4 2023).